New York Assembly Bill A09114

New York 2025-2026 Regular Session

• Introduced: 9/26/25
• Refer: 9/26/25

Caption

Prohibits the sale or offering for sale, delivery or manufacture of food or beverages containing kratom or its derivatives, or 7-hydroxymitragynine; provides penalties.

Impact

With the enactment of A09114, the landscape of food and beverage regulatory practices in New York would undergo significant changes. By banning the sale of kratom and its derivatives, the state aims to mitigate potential public health risks associated with these products. The bill is likely to affect entities involved in the herbal supplement marketplace, including manufacturers and retailers, who will need to adjust their offerings to comply with the new regulations. Additionally, it sets a precedent for the approach New York may take toward other substances deemed hazardous in the future.

Summary

Bill A09114 proposes to amend the general business law in New York by prohibiting the sale, delivery, or manufacture of food or beverages containing kratom and its psychoactive derivative, 7-hydroxymitragynine. This bill is aimed at regulating products that are marketed as herbal supplements, reflecting growing concerns over the safety of these substances. The legislation sets forth that any violations will incur civil penalties, thereby enhancing consumer protection within the food and beverage industry. This reflects a trend towards stricter oversight of products that may pose health risks to consumers.

Penalties

The bill includes specific civil penalties for violations of the ban, with fines set at up to $500 for a first offense and up to $1,000 for subsequent violations. This enforcement mechanism indicates the state's commitment to transitioning from a largely unregulated herbal supplement market to a framework that prioritizes public health and safety.

Contention

There may be notable points of contention surrounding A09114, particularly from those advocating for kratom as a useful herbal alternative for various health issues. Supporters of kratom often cite its potential benefits, such as pain relief and reduced anxiety, positioning it as a less addictive substitute to opioids. Opponents of the bill, conversely, emphasize the lack of comprehensive research regarding the safety and efficacy of kratom. As states across the U.S. consider regulations on this substance, the discussions surrounding A09114 reflect broader debates over the balance between consumer safety and personal choice in health and wellness.